Lisata Therapeutics Inc (NASDAQ: LSTA)’s stock price has gone rise by 12.90% in comparison to its previous close of $2.48, however, the company has experienced a -3.42% decrease in its stock price over the last five trading days. proactiveinvestors.com reported 2025-06-26 that Lisata Therapeutics Inc (NASDAQ:LSTA), in collaboration with the Australasian Gastro-Intestinal Trials Group and the NHMRC Clinical Trials Centre at the University of Sydney, announced positive preliminary results from Cohort B of the ASCEND Phase 2b clinical trial evaluating certepetide in combination with standard-of-care chemotherapy in metastatic pancreatic ductal adenocarcinoma (mPDAC). The ASCEND trial is a 158-patient, double-blind, randomized, placebo-controlled study assessing the addition of certepetide to standard-of-care gemcitabine and nab-paclitaxel.
Is It Worth Investing in Lisata Therapeutics Inc (NASDAQ: LSTA) Right Now?
Company’s 36-month beta value is 0.95.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for LSTA is 6.72M, and currently, short sellers hold a 0.46% ratio of that floaft. The average trading volume of LSTA on July 09, 2025 was 14.14K shares.
LSTA’s Market Performance
The stock of Lisata Therapeutics Inc (LSTA) has seen a -3.42% decrease in the past week, with a 5.66% rise in the past month, and a 40.70% gain in the past quarter. The volatility ratio for the week is 11.77%, and the volatility levels for the past 30 days are at 9.18% for LSTA. The simple moving average for the past 20 days is 7.72% for LSTA’s stock, with a 4.69% simple moving average for the past 200 days.
LSTA Trading at 10.53% from the 50-Day Moving Average
After a stumble in the market that brought LSTA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.33% of loss for the given period.
Stock Fundamentals for LSTA
Current profitability levels for the company are sitting at:
- -15.81 for the present operating margin
- 0.91 for the gross margin
The net margin for Lisata Therapeutics Inc stands at -19.31. The total capital return value is set at -0.63. Equity return is now at value -56.49, with -50.01 for asset returns.
Currently, EBITDA for the company is -22.23 million with net debt to EBITDA at 1.32. When we switch over and look at the enterprise to sales, we see a ratio of 3.86. The receivables turnover for the company is 1.33for trailing twelve months and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.52.
Conclusion
In a nutshell, Lisata Therapeutics Inc (LSTA) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
